Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives $172.14 Consensus PT from Brokerages
Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has earned a consensus rating of “Buy” from the fifteen research firms that are presently covering the stock, Marketbeat reports. Fourteen analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target […]
Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has earned a consensus rating of “Buy” from the fifteen research firms that are presently covering the stock, Marketbeat reports. Fourteen analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target […]
